The global Liquid Biopsy Market, valued at US$3.65 billion in 2024 stood at US$4.03 billion in 2025 and is projected to ...

PanTracer LBx will strengthen NeoGenomics’ pan-solid tumor CGP portfolio and position it in the growing $3 to $5 billion ...

While the liquid biopsy technology continues to evolve for lung cancer management, researchers are working toward further ...

UChicago researchers have developed a new blood test that uses RNA modifications to detect early-stage colorectal cancer with 95% accuracy ...

In a pioneering collaboration aimed at transforming pediatric cancer diagnostics and research, Dana-Farber Cancer Institute, ...

NeoGenomics launched the NEO PanTracer™ LBx, a blood-based comprehensive genomic profiling test, expanding the company’s ...

A groundbreaking study reveals that Guardant Reveal's liquid biopsy detects immunotherapy responses earlier, enhancing ...

According to MarketsandMarkets™, The seed technologies market is projected to reach USD 14.50 billion by 2030 from USD 9.35 billion in 2025, ...

Analysts anticipate Exact Sciences to report an earnings per share (EPS) of $0.02. Anticipation surrounds Exact Sciences's ...

Liquid biopsy is a new technique that makes it easier to identify and monitor lung cancer without surgery. In India, this ...

Guardant Health raised its FY2025 sales guidance from $880.00 million-$890.00 million to $915.00 million-$925.00 million.